Insider Cluster (3 insiders) ·Filed May 21, 2026

NBIX

NEUROCRINE BIOSCIENCES INC
BEARISH
Impact 5/10
Horizonweeks Processed4mo ago
Insider cluster: 3 insiders, $40.8M total
Actionable Insight ▼ Bearish

Monitor for further insider selling in the coming weeks, especially if additional director/executive sales emerge. The post-acquisition selling pattern is not alarming by itself, but sustained selling could signal reduced confidence in near-term integration prospects.

DirectionBearish
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
NBIX ▼ -1.45% at T+60d
SHORT call ✓ call won +1.45% · α vs SPY +4.37% · entry $156.50 → $154.23
Entry anchored
May 21, 2026
via day open
T+1d
-0.50%
call +0.50% · α +1.08%
$155.72
settled 4mo ago
T+5d
+2.54%
call -2.54% · α -0.89%
$160.48
settled 4mo ago
T+20d
+3.27%
call -3.27% · α -3.44%
$161.62
settled 3mo ago
T+60d
-1.45%
call +1.45% · α +4.37%
$154.23
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Two NBIX directors sold shares totaling ~$40.8M following the closing of the $2.9B Soleno acquisition, representing modest insider selling (0.26% of market cap). The sales coincide with option exercises and may reflect routine portfolio rebalancing rather than a negative business outlook, but the timing post-deal close warrants monitoring.

Key Financial Metrics

Direction
selling
Total Value
$40.8M
Insiders
3

Key Facts

  • Three directors sold shares: Kevin Gorman ($37.8M), Richard Pops ($2.4M), Leslie Norwalk ($0.6M) between May 12-19, 2026.
  • Total insider sales: $40.78M, representing ~0.26% of NBIX's $15.6B market cap.
  • Sales occurred shortly after the closing of the $2.9B Soleno Therapeutics acquisition on May 18, 2026.
  • All sales were accompanied by concurrent option exercises (non-cash) at lower strike prices.

Financial Impact

$40.78M in insider sales, ~0.26% of market cap

insider ownershipdilution from option exercises

Risk Factors

  • Additional insider sales may pressure the stock in the short term.
  • Integration of Soleno's VYKAT XR could face commercial or regulatory hurdles.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (35 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NBIX-1779400217159
17 reports for NBIX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NBIX — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 3/10
$149.50 $139.49▼ −6.70%▼ −9.26%$143.18 (−4.23%)
Jul 13, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$174.10 $170.88▼ −1.85%▼ −1.06%$143.18 (−17.76%)
Jul 9, 2026
12w ago
Press Release
NEUTRAL ★ 2/10
$177.11 $171.55▼ −3.14%▼ −2.58%$143.18 (−19.16%)
Jun 9, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$160.86 $156.42▼ −2.76%▼ −6.19%$143.18 (−10.99%)
Jun 8, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$165.24 $159.51▼ −3.47%▼ −5.88%$143.18 (−13.35%)
Jun 8, 2026
16w ago
Insider Cluster
NEUTRAL ★ 4/10
$165.24 $159.51▼ −3.47%▼ −5.88%$143.18 (−13.35%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$163.88 $159.76▼ −2.51%▼ −3.08%$143.18 (−12.63%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$164.23 $160.86▼ −2.05%▲ +1.77%$143.18 (−12.81%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$164.23 $160.86▼ −2.05%▲ +1.77%$143.18 (−12.81%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$164.23 $160.86▼ −2.05%▲ +1.77%$143.18 (−12.81%)
Showing 10 of 17

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 21, 2026